On March 9, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022 (Press release, Infinity Pharmaceuticals, MAR 9, 2022, View Source [SID1234609760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

32nd Annual Oppenheimer Healthcare Conference (virtual)

Date: March 16th, 2022

Time: 2:40pm – 3:10pm ET

Speaker: Adelene Perkins, Chief Executive Officer

Format: Company Presentation

Webcast Registration Link.

*a replay will be available following the presentation for 90 days